

**Bimekizumab complete clearance of both skin and nail psoriasis:
Comparative efficacy in phase 3/3b studies**

Joseph F. Merola,¹ Richard B. Warren,^{2,3} Diamant Thaçi,⁴ Kenneth B. Gordon,⁵
Emi Nishida,⁶ Bruce Strober,^{7,8} Curdin Conrad,⁹ Sarah Kavanagh,¹⁰ José
Manuel López Pinto,¹¹ Bengt Hoepken,¹² Paolo Gisondi¹³

¹Department of Dermatology and Department of Medicine, Division of
Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA;

²Dermatology Centre, Northern Care Alliance NHS Foundation Trust,
Manchester, UK; ³Division of Musculoskeletal and Dermatological Sciences,
Manchester Academic Health Science Centre, University of Manchester,
Manchester, UK; ⁴Institute and Comprehensive Center for Inflammation

Medicine, University of Lübeck, Lübeck, Germany; ⁵Department of
Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;

⁶Nagoya City University West Medical Center, Nagoya, Japan; ⁷Department of
Dermatology, Yale University, New Haven, Connecticut, USA; ⁸Central
Connecticut Dermatology Research, Cromwell, Connecticut, USA;

⁹Department of Dermatology, University Hospital Lausanne, Lausanne,
Switzerland; ¹⁰UCB, Morrisville, North Carolina, USA; ¹¹UCB, Madrid, Spain;


¹²UCB, Monheim am Rhein, Germany; ¹³Section of Dermatology and
Venereology, Department of Medicine, University of Verona, Verona, Italy

Correspondence to: Paolo Gisondi (paolo.gisondi@univr.it), Section of
Dermatology and Venereology, Department of Medicine, University of Verona,
Verona, Italy, Tel +39 45 812 2547 Fax +39 45 802 7315

Journal: American Journal of Clinical Dermatology 2025


SUPPLEMENTARY INFORMATION


Supplementary Figure 1. Summary of included patients




^aAdalimumab dosed 80 mg at baseline, 40 mg at Week 1, then 40 mg Q2W to Week 24, followed by bimekizumab Q4W; ^bDosing based on bodyweight at baseline: 45 mg for patients weighing ≤100 kg, and 90 mg for patients weighing >100 kg, received at baseline and Week 4, then Q12W; ^cDosed 300 mg weekly to Week 4, then Q4W; ^dBE SURE ran for 56 weeks, BE VIVID ran for 52 weeks and BE RADIANT ran for 48 weeks; ^eAt BE RADIANT Week 64, or the next scheduled clinic visit, patients receiving BKZ Q4W switched to Q8W after the implementation of a protocol amendment; ^fAt BE BRIGHT OLE Week 24, patients receiving BKZ Q4W who achieved ≥PASI 90 could switch to Q8W, at the investigator's discretion; ^gFollowing a protocol amendment, at BE BRIGHT OLE Week 48 or the next scheduled clinic visit, all patients receiving BKZ Q4W switched to Q8W dosing.

Supplementary Figure 2. Concurrent mNAPSI 0 and BSA $\leq 1\%$ in patients with nail involvement (mNRI, OC)







OC, % (n/N_{obs})

SEC/BKZ (N=155)

BKZ Total (N=182)

BKZ Q4W/Q8W (N=100)

Year 1
(Week 48)

52.3 (80/153)

74.6 (132/177)

81.3 (78/96)

Year 2
(Week 96)

73.2 (104/142)

72.0 (118/164)

73.3 (66/90)

Year 3
(Week 144)

66.9 (93/139)


74.8 (113/151)


79.0 (64/81)


a) Over 4 years in BE SURE/BE BRIGHT; b) Over 4 years in BE VIVID/BE BRIGHT; c) Over 3 years in BE RADIANT. Kinetic plots report mNRI, tables report OC. BKZ Total represents all bimekizumab dose groups combined. Only patients with nail involvement (mNAPSI >0) at baseline who entered the OLEs were included in the analysis. ADA: adalimumab; BKZ: bimekizumab; BSA: body surface area; mNAPSI: modified Nail Psoriasis Severity Index; mNRI: modified non-responder imputation; OC: observed case; Q4W: every 4 weeks; Q8W: every 8 weeks; SEC: secukinumab; UST: ustekinumab.

Supplementary Figure 3. Concurrent mNAPSI 0 and PASI ≤1 in patients with nail involvement (mNRI, OC)

a)







a) Over 4 years in BE SURE/BE BRIGHT; b) Over 4 years in BE VIVID/BE BRIGHT; c) Over 3 years in BE RADIANT. Kinetic plots report mNRI, tables report OC. BKZ Total represents all bimekizumab dose groups combined. Only patients with nail involvement (mNAPSI >0) at baseline who entered the OLEs were included in the analysis. ADA: adalimumab; BKZ: bimekizumab; mNAPSI: modified Nail Psoriasis Severity Index; mNRI: modified non-responder imputation; OC: observed case; PASI: Psoriasis Area and Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks; SEC: secukinumab; UST: ustekinumab.